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Abstract 
Management of type 2 diabetes mellitus (T2DM) is essential from cost and treatment 
perspectives. In 2017, costs associated with diabetes management in the United States 
amounted to approximately $327 billion. The treatment of T2DM has been in a dynamic 
state for the past several years with the arrival of new classes of medications and new 
data supporting the use of diabetes medications to reduce risks from cardiovascular 
disease and slow the decline of renal function. This project explored the current evidence 
on treatment of T2DM to support changing either the flow of the current protocol 
algorithm or the medications identified in the algorithm. Current evidence and guidelines 
for the treatment of T2DM were reviewed and critically appraised using the levels of 
evidence for prognostic studies guideline.  Knowles’s theory of adult learning guided this 
project. Current evidence supported the recommendation to maintain the current protocol 
algorithm. A 2-member expert panel AGREE II tool review revealed their support of the 
current protocol.  The expert panel indicated strong agreement with 98% of the items and 
agreement with the remaining 2%.  The recommendation to continue the protocol 
algorithm was presented to the diabetes council. Treating T2DM patients using the most 
current recommendations can support improved quality of life for patients and families. 
Decision-making authority by nurse-led groups such as the diabetes council will promote 
positive social change within the organization. 
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Section 1: Nature of the Project 
Introduction 
A local health care system developed an algorithm for use in management and 
treatment recommendations for type 2 diabetes mellitus (T2DM). Under U.S. Food and 
Drug Administration (FDA) guidelines, many T2DM medications have received 
approvals for the treatment of additional diseases other than T2DM. This project explored 
the present evidence related to T2DM medications and determined if they are appropriate 
for use while considering the new FDA recommendations. A revised algorithm was then 
presented to an expert panel.  
Problem Statement 
Obesity is one of the two most significant risk factors for the development of 
T2DM (Raghavan et al., 2016). Reported as between 30% and 35%, Pennsylvania’s 
obesity rate places the state in the second-highest category of states ranked by obesity 
prevalence (Centers for Disease Control and Prevention [CDC], 2017). T2DM affects 
nearly 22 million people in the United States (CDC, 2018). T2DM has been identified as 
the seventh leading cause of death in the United States,with an expected cost of $327 
billion in 2017 (American Diabetes Association [ADA], 2019). With approximately one-
third of Pennsylvania residents at higher risk for developing T2DM, nurses in the state 
must be ready and prepared to treat this growing population with efficiency and efficacy 
to control diabetes. Nurses play an integral role in T2DM management (Essien et al., 
2017).  
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The health care system involved with this project is a Magnet-level-designated 
hospital. As a requirement of Magnet status, each facility must show the use of evidence-
based materials in its treatment plans (American Nurses Credentialing Center, n.d.). To 
meet this requirement, a standardized algorithm for the treatment and management of 
T2DM patients was developed by the health system’s diabetes care committee. The 
committee included the heads of various departments in the hospital, so approval for the 
use of the algorithm stayed with the committee. The algorithm was designed to provide 
direction for staff who work in diabetes management. The algorithm serves as a resource 
to guide the suggested order of medication management in the treatment of T2DM. The 
current algorithm, based on data that are nearly two years old, does not include references 
or supporting evidence.  A review of the literature was completed to identify whether the 
current flow remains the best flow based on the evidence found in the review. The review 
also served to provide proof of the quality of the information in the protocol. Lastly, the 
discussion served to help reintroduce the protocol to the nursing providers. 
Recommendations for any additions or changes were presented to the diabetes care 
committee and nursing educators. 
Purpose 
The members of the diabetes care committee identified through medication-use 
reports completed by the hospital that many practitioners were not using the algorithm to 
drive their thought processes in T2DM management. Given that T2DM management has 
changed dramatically over the past 5 to 10 years, it is imperative that practitioners not 
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only are aware of the most up-to-date medications and interventions, but also have an 
evidence-based tool to use to standardize and guide T2DM management.  
The practice-focused question for this project was the following: Does the current 
evidence on treatment of T2DM support changing either the flow of the current algorithm 
or the medications identified in the algorithm? This project supported the use of the 
algorithm from both a quality standpoint and a quantity standpoint. Dissemination of this 
project will serve to assist in the improvement of the quality and quantity of T2DM care 
within the health care system. 
Nature of the Doctoral Project 
The Walden University Library was used to explore most of the data to be 
collected. The following databases were accessed: 
• CINAHL 
• MEDLINE 
• ProQuest 
• PubMed 
• Annual Reviews 
• Cochrane Database of Systematic Reviews 
• CINAHL Plus 
• Database of Abstracts of Reviews of Effects (DARE) 
Keywords included but were not limited to diabetes, obesity, education, 
outcomes, management, and treatment. Additional relevant terms were included when 
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identified. Inclusion and exclusion criteria were identified.  Literature was reviewed from 
2014 to the present. Only literature written in English was reviewed. The project 
followed the guidelines defined in the Walden University Manual for Clinical Practice 
Guideline Development. 
Active dissemination of this project served as a catalyst to bring the topic of 
diabetes management to the forefront and provide a standardized, evidence-based method 
of control for nurses when working with patients with T2DM. The system for which this 
project was developed is a Magnet hospital. Having evidence-based data will serve to 
support one of the requirements for Magnet status. Additionally, ensuring that nurse 
educators have current knowledge of diabetes medication management is expected to 
improve the quality of the nurses’ education and patients’ knowledge. Nursing education 
continues to grow in importance, and evidence-based data improve the quality of this 
education. With an increase in educational excellence, one can expect a community to 
become better educated. The premise is that better education leads to better health and 
lower health care costs (Odnoletkova et al., 2016). 
Significance 
Stakeholders in this project included hospital administrators, direct caregivers, 
patients, and families.  Affecting nearly 10% of the population in the United States, 
T2DM has the potential to change almost every household. The effects of T2DM include 
financial treatment costs (e.g., for medications, copayments and deductibles, and 
transportation) as well as nonfinancial costs related to decreased quality of life resulting 
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from complications of diabetes. Use of the most effective drugs can promote the most 
effective management of this disease, decreasing hospitalization costs and loss of work 
time. Adherence to the most recent recommendations for treating T2DM has implications 
for positive social change, in that it promotes higher quality of life for patients and their 
families.  
Summary 
T2DM incurs significant costs to the U.S. healthcare system. Section 1 introduced 
the use of a standardized treatment algorithm that may reduce health care costs and 
improve the evidence-based care of patients with T2DM. The practice-focused question 
for this project was the following: Does the current evidence on treatment of T2DM 
support changing either the flow of the current algorithm or the medications identified in 
the algorithm? This algorithm will serve as the foundation for nursing education and 
medication management for persons with T2DM. Section 2 introduces the model 
supporting this project. Literature supporting the project’s relevance to nursing practice is 
discussed. My role in the system is clarified, along with that of the project team. 
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Section 2: Background and Context 
Introduction 
The practice-focused question for this project was the following: Does the current 
evidence on treatment of T2DM support changing either the flow of the current algorithm 
or the medications identified in the algorithm? In this section, I define the methods as the 
basis for this project, including the reasoning to support the use of each method. An 
established algorithm provides a structured document to nurse educators to guide them in 
diabetes medication management and optimization. The leaders of a local health care 
system felt that it was necessary to devise such an algorithm to provide uniformity, 
direction, and support in medication use and management for T2DM patients. This 
project provided evidence-based support and background for reviewing the current 
algorithm and offering evidence-based recommendations for change. Ultimately, the goal 
was to improve the consistency and quality of nursing education for T2DM medication 
management.  
Concepts, Models, and Theories 
T2DM affects about 9.4% of the U.S. population (CDC, 2017). A recent report 
estimated the total cost of managing diabetes in the United States at $327 million, 
indicating a cost increase of 26% over the previous 5 years (ADA, 2019). These data 
support the importance of diabetes management to nursing and the need to provide 
evidence-based education to improve management efforts. 
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I applied Knowles’s principles of andragogy in reviewing how this project meets 
the needs of adult learners. Table 1 aligns the project with Knowles’s model. 
Table 1 
Knowles’s Theory of Adult Learning 
Principles Relationship to project 
1: Self-concept The adults using this algorithm will exhibit self-
confidence and show independent thought processes and 
teaching. 
2: Adult learner experience With each opportunity to use the algorithm, users will 
grow in their knowledge base and share this in their 
teaching. 
3: Readiness to learn As the material is presented, users will increasingly 
become more aware of their need to meet learners’ 
needs. 
4: Orientation to learning Each time this material is used, users will learn the 
concepts behind the algorithm and work toward 
education for diabetes management with consideration 
of the patient’s needs. 
5: Motivation to learn This provides the basis for diabetes management and 
allows users to promote self-reflection and self-growth 
in their knowledge base.  
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Relevance to Nursing Practice 
Diabetes is a significant economic drain on the U.S. economy and health care 
system, not including only the cost of providing care to persons with diabetes but also the 
indirect health care costs. Nurses are in an ideal position to help control these costs with 
the use of evidence-based algorithms. This document will serve to either support the 
current algorithm or provide current evidence-based information to bring the algorithm 
current This project served as the catalyst to increase the dissemination of this material 
with both an evidence-based and nursing-based focus for use in diabetes educator 
sessions.  
Multiple certifications are available for nurses to obtain as an indication of their 
level of competency in relation to diabetes education. One such certification is Certified 
Diabetes Educator (CDE) certification from the National Certification Board for Diabetes 
Educators (NCBDE). This certification requires a position as a diabetes educator and 
some level of licensure, such as that of a nurse, dietician, or pharmacist. The majority of 
the focus of the NCBDE is on the education of the patient, with a smaller focus on 
medication management (NCBDE, n.d.) Additionally, a Board Certification—Advanced 
Diabetes Management (BC-ADM) credential is available from the American Association 
of Diabetes Educators (AADE). This certification is for licensed individuals with 
master’s degrees or higher who work in a diabetes education role. The focus of this 
certification program is stronger medication management during diabetes education, as 
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well as more in-depth, more global review of patients with diabetes and how to best meet 
their needs. However, in the local system, only a few CDEs also hold nursing licenses. 
There are currently three educators who hold the BC-ADM certification: two nurses and 
one pharmacist.  
Terens et al. (2018) identified disparities within diabetes education and 
recommended the use of superior evidence-based material to educate patients with 
diabetes. The use of an evidence-based algorithm will undoubtedly work toward meeting 
this requirement.  
Diabetes treatments date back some 3,500 years, but all current diabetes 
medications have been developed since the 1920s (White, 2014). As several new classes 
of drugs were developed within the past 15 years, it became apparent that many nurses 
and practitioners have not kept themselves current with the latest drugs. Therefore, older 
drugs continue to be used that do not have the additional benefits that many of the new 
drugs have been proven to offer.  
In the subsections that follow, diabetes medications are listed in the order of 
recommended use. I review each medication’s advantages, side effects, and 
contraindications and provide the cash price (using GoodRx) for a 30-day supply based 
on a single location in central Pennsylvania (GoodRx, n.d.).  
Metformin (Biguanide) 
Metformin was the first medication on the algorithm recommended for use as the 
initial medication. Metformin brings a slight reduction in the risk for colorectal cancer 
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(Higurashi et al., 2016). Studies have indicated a possible cardiovascular (CV) risk 
reduction, but data from multiple studies lack consistency in indicating a clear link to CV 
risk reduction (Griffin et al., 2017). Metformin was associated with approximately a 2-
point decrease in A1c (Chung, Hartzler, Smith, Hatton, & Kelley, 2018). 
Metformin carries a low risk of side effects, with the most common side effect 
being gastrointestinal upset. Blonde and colleagues (2004) found that the use of 
extended-release metformin was associated with nearly a halving of side effects as 
compared to the use of immediate-release metformin. An additional concern that has 
been raised regarding the use of metformin is that metformin is linked with an increased 
risk of acidosis. However, recent studies have indicated that there is no increased risk of 
acidosis as long as the estimated glomerular filtration rate (eGFR) remains above 30 
ml/min (Lazarus et al., 2018).  
In 2016, the FDA issued revised guidelines indicating that metformin use was 
safe in patients with decreased kidney function. This revised guideline allowed increased 
use of metformin for those patients with an eGFR between 30ml/min and 60ml/min.  
The typical cash price for a 2,000-milligram daily dose of metformin is between 
$11.76 and $37.19 per month. This medication is taken as oral pills daily. Of note is that 
metformin is the generic name of this class of drugs. There are several brand names 
available at higher cost than the generic version. 
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Liraglutide (Victoza®; Glucagon-Like Peptide 1 Receptor Agonist [GLP1]) 
Liraglutide, the second-choice medication, brings several advantages with its use. 
The Liguratide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 
Results (LEADER®) trial used a large cohort of subjects with established CV disease. 
The trial demonstrated a 22% reduction in death from CV causes, a 12% reduction in 
nonfatal myocardial infarctions (MI), and an 11% reduction in nonfatal stroke among its 
study group as compared to the control group (a total of 9,340 patients; Marso, Daniels, 
et al., 2016). Additionally, Victoza demonstrated A1c lowering at 1.8 after 26 weeks, as 
well as weight reduction of more than 7 pounds after the same 26-week period.  
Victoza® has a relatively high rate of side effects (nausea, 20%; diarrhea, 12%) 
with its use, with gastrointestinal side effects representing the most significant 
percentage. Other side effects include headache, nasopharyngitis, vomiting, decreased 
appetite, dyspepsia, which occurred at rates of 7% to 10% among those in the study 
(NovoNordisk, 2017). The product also carries a pancreatitis warning. However, the raw 
data support that the incidence of pancreatitis was lower for those on Victoza than for 
those in the control group. This medication also carries a low risk of hypoglycemia 
(NovoNordisk, 2017). This medication is only available as a once-daily injection and as a 
brand-name medication. Generic versions are not yet available. There are several other 
GLP1 medications available, but they have not yet demonstrated any CV risk reduction in 
clinical trials.  
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Victoza® also carries a “black box” warning regarding the possible risk of thyroid 
C-cell tumors (NovoNordisk, 2017). The data support that increased incidence of tumors 
appeared only in rats during the medication’s original trial. There have not been reports 
of any human cases of C-cell tumors believed to have been caused by Victoza®. The 
cash price for Victoza® for the maximum dose of 1.8 mg injected daily is between 
$872.85 and $934.40 per month.  
Empagliflozin (Jardiance®; Sodium Glucose Cotransporters [SGLT2 Inhibitor]) 
The third-choice medication also brings several advantages with its use. The 
EMPA-REG trial showed CV risk reduction not dissimilar to that seen in the Victoza 
trial. Empagliflozin showed a 38% reduction in CV death and a 35% reduction in 
hospitalization for heart failure (Zinman et al., 2015). A1c reduction and weight 
reduction were also evident in the EMPA-REG trial. A1c levels reduced by 0.6, and 
weight reduced by 2.1kg (Boehringer Ingelheim Pharmaceuticals, Inc., 2017a). 
Side effects of Jardiance® include urinary tract infections and mycotic infections, 
particularly in females, with incidence ranging from 5.4% to 9.3% (Boehringer Ingelheim 
Pharmaceuticals, Inc., 2017a). The product information addresses the risk of developing 
diabetic ketoacidosis and volume depletion due to increased urination; however, this side 
effect is not listed in the side effects table (Boehringer Ingelheim Pharmaceuticals, Inc., 
2017a). Jardiance® carries a low risk of hypoglycemia (Boehringer Ingelheim 
Pharmaceuticals, Inc., 2017a). Jardiance® is not approved for use in persons with an 
eGFR of < 45 ml/min (Boehringer Ingelheim Pharmaceuticals, Inc., 2017a); this may 
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limit the number of people with diabetes who can use this medication. Jardiance® is 
available as an oral tablet to be taken once daily. Typical costs range from $381.11 to 
$449.07 for a 1-month supply (GoodRx, n.d.). 
Linagliptin (Tadjenta®; Dipeptidyl Peptidase-4 [DPP-4] Inhibitors) 
This fourth class of medications, called DPP-4, includes three different 
medications. Of these three, linagliptin is the only one that is not renally excreted, such 
that no dose adjustment is necessary based on renal function (McKeage, 2014). 
Linaglipitin has not been shown to increase CV risks and is considered neutral for CV 
risk reduction. Linagliptin use has shown a decrease of 0.7points in their A1c.. 
Side effects listed include pancreatitis, the potential for heart failure 
(demonstrated in the other two medications in this class), severe joint pain, and bullous 
pemphigoid (Boehringer Ingelheim Pharmaceuticals, Inc., 2017b). As with many other 
medicines, linagliptin is contraindicated for persons with any hypersensitivity to it. 
Monthly costs for this medication range from $356 to $499 for a 30-tablet supply 
(GoodRx, n.d.). 
Sulfonylureas 
Sulfonylureas are an older class of medications with a broad base of users.  This 
class of drugs is also associated with low cost, which makes the use of sulfonylureas even 
more attractive to many. Side effects include a higher risk of hypoglycemia than with 
nearly all other diabetic medications; additionally, sulfonylureas are associated with a 
small amount of weight gain with use (Costello & Shivkumar, 2018). Contraindications 
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are hypersensitivities to the medicines. It is a general belief that sulfonylureas should be 
avoided in persons with a severe sulfa allergy (Costello & Shivkumar, 2018). Of note, 
sulfonylureas are negatively associated with CV risk reduction (D. A. Smith, 2017).  
The remaining two classes of medications on the algorithm are basal and bolus 
insulins. These are not reviewed because of the number of choices available for basal and 
bolus insulins; moreover, these medications are used when all of the other medications 
have not been effective in lowering blood sugars (ADA, 2018). 
Thiazolidinediones 
The last class of medications to be discussed is the thiazolidinediones (TZDs). 
This class of drugs has been found to have mixed CV risks. Of the two TZDs currently 
available, pioglitazone appears to reduce heart attack (19% reduction) and stroke (18% 
reduction) but increases the risk for heart failure (210% increase; Chi et al., 2017). They 
are contraindicated in persons with a high risk of or history of heart failure (Chi et al., 
2017). In my practice as a BC-ADM, I see little to no use of the TZD class of 
medications. The cost of pioglitazone ranges from no cost to $90 per month (GoodRx, 
n.d.).  
   With the development and use of newer medications, T2DM management has 
become more complex. Currently, there is evidence that many of these medications have 
benefits in addition to their blood-sugar-lowering effects. Using evidence-based 
information and an evidence-based algorithm can serve as a useful basis to not only 
improve diabetes management, but also incorporate other disease-risk-reduction effects in 
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the treatment protocol. This has the potential to lower the cost of T2DM management 
more than just reducing blood sugar level. 
Additional Medications 
Medications not included in the algorithm include α-glucosidase inhibitors and 
thiazolidinediones. The α-glucosidase inhibitor to be discussed is Acarbose (Precose®). 
Acarbose has shown to reduce CV risk in all measures, including stroke and heart failure, 
by about 35%. Heart attack risk was reduced by about 65% (Chi, Snaith, & Gunton, 
2017). The medication is associated with a low to moderate risk of gastrointestinal upset 
in many people (Standl et al., 2014). This medication is typically taken by mouth with the 
first bite of every meal (usually three times a day). A typical 1-month supply of tablets 
costs between $10 and $30 (GoodRx, n.d.). 
Local Background and Context 
Leaders at this health care system located in the northeastern United States found 
that diabetes continued to increase in prevalence, bringing increased costs. The diabetes 
management algorithm is one tool that the health care system has implemented to help 
control these costs. The current belief is  to avoid using higher cost medications. Their 
thought is that this would control the cost of diabetes, and health care must control 
today’s price of treatment. The leaders of the local health care system have taken this 
philosophy to the next level in that they are looking to use medications that will decrease 
the risks of CV and renal complications in the future. This algorithm uses current 
evidence-based drugs to achieve this goal.  
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Previously, research was conducted to evaluate efficacy and safety when 
medications were pending FDA approval. In 2008, the FDA mandated that all new 
applications for drug approvals must include CV data. As a result of this requirement, 
many of the newer diabetes medications now have CV data (R. J. Smith et al., 2016). 
Consequently, some diabetes medications are currently being considered for use for CV 
risk reduction in addition to diabetes control. This has introduced a new factor in diabetes 
management and, therefore, this is on reason for the health care system’s development 
and use of their diabetes algorithm. 
Role of the DNP Student 
My role in this project was to review the current algorithm, verify evidence, and 
make recommendations.  I presented the revised proposals to the health care system’s 
administration and the diabetes care transformation committee (DCTC). Although not 
part of this project, once the revisions are approved, I will promote the distribution and 
use of the diabetes algorithm. Only when the algorithm is available and in use will it 
realize its potential to reduce long-term diabetes costs by reducing CV risks and slowing 
renal decline. 
Role of the Project Team 
The project team consisted of members of the DCTC committee, who served as 
an expert panel reviewing the proposed changes to the algorithm. Members included the 
medical director of the health care system, chair of the endocrinology department, and 
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outpatient and inpatient stakeholders for improving diabetes care and outcomes in the 
system.  
Summary 
The practice-focused question for this project was the following: Does the current 
evidence on treatment of T2DM support changing either the flow of the current algorithm 
or the medications identified in the algorithm? In Section 2, I discussed Knowles’s theory 
of adult learning, evidence relevant to nursing practice, the local context for this project, 
and my role. In Section 3, I discuss the process for the revision of the clinical practice 
guideline. 
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Section 3: Collection and Analysis of Evidence 
Introduction 
The purpose of this project was to explore current evidence related to T2DM 
management. This evidence was used to update the current diabetes management 
algorithm used by a facility in the northeastern United States. Section 3 identifies the 
scope of the review of current recommendations and revision of the algorithm. 
Practice-Focused Question 
The practice-focused question for this project was: Does the current evidence on 
treatment of T2DM support changing either the flow of the current algorithm or the 
medications identified in the algorithm?  
Evidence Generated for This Project 
This project followed the steps in the Walden University Doctor of Nursing 
Practice (DNP) Manual for Clinical Practice Guideline Development. Sources of 
evidence reviewed from the Walden University online database included CINAHL, 
MEDLINE, ProQuest, PubMed, Cochrane Database of Systematic Reviews, Database of 
Abstracts of Reviews of Effects (DARE), and Google Scholar. Inclusion criteria applied 
to sources of evidence from 2015-2019 that were written in English and published in 
peer-reviewed journals. Individual medications’ product information (PI) sheets, as 
currently approved by the FDA, also served as resources for this project. Other sources of 
evidence included position statements by the ADA and the American Association of 
Clinical Endocrinologists (AACE). These sources are dynamic resources, in that they 
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undergo review each year, after which new or updated recommendations are published. 
The year 2018 marked the first time that the European Association for the Study of 
Diabetes (EADS) partnered with the ADA in releasing a consolidated recommendation, 
“Management of Hyperglycemia in Type 2 Diabetes (2018), a Consensus Report by the 
American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes (EASD)” (Davies et al., 2018). New for 2019 was the American College of 
Cardiologists position endorsement of the 2019 ADA Standards of Medical Care 
(American College of Cardiology, 2019).  
Search terms included type 2 diabetes mellitus, medications and type 2 diabetes 
mellitus, atherosclerotic CV disease risk, atherosclerotic CV disease risk, and type 2 
diabetes mellitus, the individual names of currently approved drugs for type 2 diabetes 
mellitus treatments, and Association of Clinical Endocrinologists and diabetes. 
Evidence Generated for the Doctoral Project 
The project followed the steps outlined in the Walden University DNP manual for 
clinical practice guideline development, which I have summarized in the subsections that 
follow. 
Step 1: Critically Appraise the Evidence 
I used the following levels of evidence for prognostic studies to synthesize the 
level of evidence (American Society of Plastic Surgeons, 2020): 
I High-quality prospective cohort study with adequate power or systematic 
review of these studies 
20 
 
II Lesser quality prospective cohort, retrospective cohort study, untreated 
controls from an RCT, or systematic review of these studies 
III Case-control study or systematic review of these studies 
IV Case series 
V Expert opinion; case report or clinical example; or evidence based on 
physiology, bench research, or “first principles” 
  T2DM management has become more complicated during the past 20 years. 
During the past 10 years, there have been five new classes of diabetes medications 
approved by the FDA in the United States (White, 2014). This intake of new classes of 
treatment medications has created a challenge for health care providers to keep up. 
Further, over the past decade, the FDA has mandated that CV risk data be included in 
each medication’s study trials. Many T2DM medications are now being prescribed and 
used based on CV risk reduction. No longer is lowering blood sugar the only concern 
when treating T2DM. 
Metformin (biguanide). Nearly all of the literature supported using metformin as 
the initial drug in the management of T2DM for persons who have sufficient renal 
function (Practitioners, 2015). In addition to lowering blood sugars, metformin has been 
shown to reduce CV events in persons with T2DM and a CV history (Luo et al., 2019; 
Level III). The CV risk reduction is believed to derive from the pleiotropic effects of 
metformin on the body in multiple systems (Luo et al., 2019; Level II). Numerous studies 
have also shown that metformin has anticancer properties and can destroy cancer cells 
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(Saini & Yang, 2018; Level I). As pointed out earlier, the cost of metformin is reasonable 
and affordable for most patients.  
Metformin is known to increase blood lactic acid levels; however, this is not a 
concern until a metformin overdose occurs or an outside force causes renal failure with 
increased lactic acidosis (DeFronzo et al., 2016; Level II). As a result, the FDA 
implemented new guidelines. Due to this action, the use of metformin has increased; 
however, the incidence of acidosis has not increased (DeFronzo et al., 2016; Level II). 
Another side effect is gastrointestinal distress (Siavash et al., 2017; Level II). Fortunately, 
digestive distress resolves when metformin is stopped. 
Metformin works by decreasing glucose absorption in the intestines and by 
lowering the production of glucose by the liver (Chung et al., 2018; Level II). These 
actions, in addition to a low incidence of hypoglycemia, support making metformin an 
appropriate T2DM drug to use. The literature search supports keeping metformin as the 
initial drug of choice in T2DM management. 
Victoza (liraglutide—GLP1). The entire GLP1 class of medications continues to 
evolve. As of today, there are different GLP1 medications available:  
• Adlyxin® (lixisenatide) daily use 
• Bydureon® (exenatide ER) weekly use 
• Byetta® (exenatide) twice-daily use 
• Ozempic® (semaglutide) injection weekly use 
• Rybelsus®  (semaglutide) oral daily use  
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• Trulicity® (dulaglutide) weekly use 
• Victoza® (liraglutide) daily use 
As a result of the newer entries into the class, there have been numerous studies 
completed showing CV data and therapeutic efficacy.  These multiple studies make it 
difficult to determine which specific medication shows the best value for its cost 
(Schernthaner et al., 2017; Level II). Arguably, the most promising GLP-1 medicine to 
enter the market is Ozempic®. The results of the Sustain-6 trial showed a risk reduction 
in nonfatal CVA, non-fatal heart attack, and CV death rate (Marso, Bain, et al., 2016; 
Level I). Ozempic demonstrated a significant reduction in A1c and weight in an 
additional study (Petri, Ingwersen, Flint, Zacho, & Overgaard, 2018; Level I).  
Liraglutide is the only GLP-1ra medication on the pathway. Liraglutide is known 
for several positive effects leading to improved diabetes health, such as reduction in 
weight, A1c, low-density lipoproteins (LDL), and more (Rizzo et al., 2016; Level I). At 
the time of the development of the algorithm, semaglutide had not been released. GLP1 is 
a hormone that is known as an incretin. Incretins increase insulin manufacture and insulin 
secretion, reduces glucagon generation and release, slows the emptying of the stomach, 
and help to rebuild beta cells (Chung et al., 2018; Level II). These advantages help to 
make the GLP1 class perhaps the most valuable class of medications for treating T2DM. 
Jardiance (empagliflozin—SGLT2i). Jardiance is one of four medications in the 
SGLT2 class. Other medicines in this class include the following: 
• Farxiga® (dapagliflozin) 
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• Invokana® (canagliflozin) 
• Jardiance® (empagliflozin) 
• Steglatro® (ertugliflozin) 
Of these four, canagliflozin was the first approved for use in the United States in 
2013. Since then, the other three have been released and approved by the FDA. 
Empagliflozin was the first SGLT2 released that had CV data. This CV data surprised 
many in the diabetes management community because of a significant reduction in death 
from all-cause mortality (32% reduction) and reduction in heart failure readmission by 
35% (Inzucchi et al., 2018; Level I). Since then, the other SGLT2 drugs have been shown 
to reduce CV risks and to help protect the kidneys and slow renal function decline 
(Donnan et al., 2019; Level I). Following the introduction of empagliflozin, numerous 
other SGLT2 medications have completed CV risk studies, all of which have shown some 
level of CV risk decline and slowing of renal function decline.  
A new paradigm has developed as the result of a dapagliflozin CV risk trial called 
Dapagliflozin in Patients With Heart Failure (DAPA-HF). This trial proved that 
dapagliflozin reduced CV risk, cardiac death, and heart failure decline regardless of 
whether the patient has diabetes or not (McMurray et al., 2019; Level I).  
The SGLT2 class works by preventing the reabsorption of glucose in the proximal 
renal tubule (Schork et al., 2019, p. 2; Level II).  This process then allows the glucose to 
be flushed out with the urine. The effects are glucose lowering and slight weight 
reduction due to not absorbing the calories lost in the urine.  
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Tradjenta (linagliptin—DPP4). Tradjenta is one of three medications in the 
DPP4 class approved for use in the United States. Additional drugs in this class included:  
• Januvia (Sitagliptin) 
• Onglyza (Saxagliptin) 
• Tradjenta (Linagliptin)  
The DPP4 class was approved in 2006. In 2015, the FDA released a drug safety 
communication warning of potential severe joint pain (FDA, n.d.). The DPP4 class has 
marginal A1c lowering, as shown in Figure 3. There are also limited CV data with this 
class; however, these agents do not appear to increase the risk of CV events (Gantz et al., 
2017; Level II). These concerns, coupled with the relatively high cost of these 
medications, perhaps makes their use a lower priority on the algorithm. 
Sulfonylureas. Sulfonylureas were first available in the United States in 1956, 
with second-generation sulfonylureas available in 1964 (see Table 2). First-generation 
sulfonylureas are not currently in use in the United States. However, second-generation 
sulfonylureas maintain their place in American diabetes management. One of the most 
significant advantages of using sulfonylureas is their low cost. They are available as 
generics and are inexpensive (see Table 3). They are known for a history of no CV 
benefit, weight gain, and reduced response with time (Chung et al., 2018; Level II). Other 
reviews have suggested an increase in CV risks (Azoulay & Suissa, 2017; Level I). This 
ambiguity supports that sulfonylureas should not be front-line medications for most 
persons with T2DM. 
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Thiazolidinediones (TZD—Pioglitazone [Actos]). TZD first appeared in the 
United States in 1996 (See Table 2). The first TZD, troglitazone, was short lived on the 
market due to increased liver toxicity (Temple, 2009; Level III). The use of the other 
TZDs dropped off, and their use has not become widespread, even though they are 
relatively inexpensive and can substantially reduce A1c levels (see Table 3). TZDs are 
noted for causing fluid retention leading to congestive heart failure, as well as 
osteoporosis (Rizos et al., 2016; Level II). These concerns perhaps limit the usefulness of 
this class of medications in the treatment of T2DM. 
Step 2: Synthesize the Evidence From the Literature 
Metformin remains the first-choice medication for several reasons. It is 
inexpensive, has been in the United States since the 1990s and in Europe since the 1950s, 
and has a known safety profile. These positive features, along with the pleiotropic 
benefits found, in addition to high A1c lowering, make metformin an excellent first-line 
medicine to use.  
The second choice of medication is not as clear. GLP1 agents offer the best 
weight lowering and the nearly the best A1c lowering of all the options. There is a known 
CV risk reduction. However, their high cost and the fact that most in the class are 
currently available only as injections limit their use. If someone has an aversion to an 
injectable, then an SGLT2 could be the second choice. SGLT2s offer good A1c control 
and weight lowering while providing CV risk reduction and slowing of renal function 
decline. With either choice of drug, the GLP1 or the SGLT2, CV risk reduction, A1c 
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reduction, and weight reduction can be expected to occur, making either class an 
appropriate second choice with the other as a third-choice medication. TZDs could be an 
option for those in whom osteoporosis, congestive heart failure, or fluid retention is not a 
concern. Sulfonylureas remain an option for persons with low income or medication cost 
concerns.  
The recent addition of CVD data to development trials has complicated the issue 
of choosing the most appropriate medication to treat T2DM. Ranking CVD risk reduction 
is beyond the scope of this paper and is not addressed. 
Step 3: Develop the Revised Guideline 
Based on the current evidence, the recommendation to continue the current 
protocol algorithm for T2DM was sent to the expert panel for review.  
Step 4: Expert Panel Review 
The panelists used the AGREE II instrument and made recommendations for 
revisions. Each panel member reviewed the proposed guideline in relation to the 
following domains (Brouwers et al., 2010):  
1. Scope and purpose 
2. Stakeholder involvement 
3. Rigor of development 
4. Clarity of presentation 
5. Applicability 
6. Editorial independence 
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See Section 4 for further details on this step. 
Step 5: Finalize Guideline 
See Section 4 for discussion of Step 5. 
Step 6: Present to Organization 
See Section 4 for discussion of Step 6. 
Summary 
Section 3 described the process and analysis for this project, following the 
guidelines outlined in the Walden University DNP Manual for Clinical Practice 
Guideline Development. The practice question was: Does the current evidence on 
treatment of T2DM support changing either the flow of the current algorithm or the 
medications identified in the algorithm? In Section 4, I discuss findings, implications, and 
recommendations to the organization. 
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Section 4: Findings and Recommendations 
Introduction 
The management of T2DM has become more complicated with the introduction 
of multiple medication classes over the past 10 years. The number of new medications in 
each category, along with research studies that provide CV risk reduction data, has had an 
impact on health care providers’ decision making in several ways. The recent 
introduction of newer classes of medications such as the GLP1ra and the SGLT2i has 
presented new educational challenges for practitioners (Farahani, 2015). These dynamic 
medication changes have posed barriers for many currently practicing providers in terms 
of their ability to remain up to date concerning the latest options for diabetes 
management.  
Findings and Implications 
The literature search supported the current guideline and did not reveal any 
significant changes. The current classes of medications in the guideline remain available 
and are hierarchical in their use. The ADA’s 2020 guidelines support the local algorithm. 
The AACE’s 2019 guidelines also support the use of the local algorithm due to having 
many similarities.  
I used the AGREE II tool to review the validity of the guideline. A three-person 
panel of local experts was provided the AGREE II tool and this paper to evaluate.  The 
AGREE II tool consisted of 23 questions using six domains and two overall rating 
assessments. The results of the panel’s use of the tool are documented in Table 2. 
29 
 
Table 2 
AGREE II Expert Panel Results 
Criteria Reviewer 1 Reviewer 2 Comments 
1. The overall objectives of the guidelines were specifically 
described. 
7 7 Objective was clear, concise, and 
articulated nicely. 
2. Health questions read the guideline are specifically 
described. 
7 7 Health question covered by 
guideline was described in detail. 
3. The population (patients, public, etc.) to whom the 
guideline is meant to apply is specifically described. 
7 7 T2DM is becoming an epidemic in 
our rural community. The 
prevalence of such was identified 
as well as compared at a national 
level. 
4. The guideline development group includes individuals 
from all relevant professional groups. 
7 7 It is apparent that much thought 
and research went to the stated 
population. 
5. The views and preferences of the target population 
(patients, public, etc.) have been sought. 
7 7 Subject matter experts in the field 
of diabetes management were well 
represented and utilized 
appropriately. 
6. The target users of the guideline are clearly identified. 7 7 Target users were clearly identified 
and defined. 
7. Systematic methods were used to search for evidence.  7 7 Algorithms noted throughout 
paper. 
8. The criteria for selecting the evidence are clearly 
described. 
7 7 Strong correlation noted. 
9. The strengths and limitations of the body of evidence are 
clearly described. 
7 7 Strengths and limitations were 
called out in professional 
document. 
10. The methods for formulating the recommendations are 
clearly described. 
7 7 Recommendations were clear and 
concise. 
11. The health benefits, side effects, and risk have been 
considered in formulating the recommendations. 
7 7 All noted. 
12. There is an explicit link between the recommendations 
and the supporting evidence. 
7 7 Supporting evidence was found as 
well as referenced throughout 
professional document. 
13. The guideline has been externally reviewed by experts 
prior to its publication. 
7 7 Reviewed and recommendations 
provided prior to submission. 
14. A procedure for updating the guideline is provided. 7 7 As noted in diagram. 
15. The recommendations are specific and unambiguous. 7 7 (table continues) 
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16. The different options for management of the condition or 
health issue are clearly presented. 
7 7  
17. Key recommendations are easily identified. 7 7  
18. The guideline describes facilitators and barriers to its 
application. 
7 7  
19. The guideline provides advice and/or tools on how the 
recommendations can be put into practice. 
7 7  
20. The potential resource implications of applying the 
recommendations have been considered. 
7 6  
21. The guideline presents monitoring and/or auditing 
criteria. 
7 7  
22. The views of the funding body have not influenced the 
content of the guideline. 
7 7  
23. Competing interests of guideline development group 
members have been recorded and addressed. 
7 7  
Supplemental questions    
Rating of overall quality of this guideline. 7 7 Very well written. It is clear a 
considerable amount of research 
went into this project. A well-
rounded approach using the latest 
references assisted in the paper's 
solid foundation. Extensive process 
including utilizing national best 
practices to create a well-designed 
helpful guideline for a high-volume 
diagnosis. great work 
I would recommend this guideline for use.  Yes Yes  
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Recommendations 
The result of the AGREE II tool clearly demonstrated that the expert panel 
strongly agreed with the results and the process. Out of 46 responses, there were 45 
ratings of 7 and a single rating of 6, for a 9.8% strongly agree rating. The expert panel 
nearly unanimously supported the tool in its current state. The current guideline and the 
supporting information in this paper will be presented to the DCTC group for 
consideration and review at its next meeting slated for February. This committee is the 
group that is charged with overall diabetes management and policy within the health care 
system. This committee has the power and the potential to implement change in the 
organization and is the ideal group to use as the catalyst for change. 
Strengths and Limitations of the Project 
Strengths 
 Review of the studies in my literature review indicated that each study was 
powered and designed to prove non-inferiority or superiority against a lesser agent or no 
agent. The studies used varied population groups and different methodologies, with 
similar outcomes measured in A1c lowering. Most of the studies used large population 
numbers, lending additional support to their validity.  These variabilities included a 
diverse population with large numbers, all sharing a common outcome of A1c 
measurement. Many studies also used a placebo-controlled trial, leading to a higher 
quality of information (Möller, 2011). The panel of experts unanimously supported this 
tool, providing a level of agreement and support within the organization. 
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Limitations 
Lack of participation by one of the members of the expert panel diluted the use of 
the AGREE II tool; however, the experts nearly 100% agreed with the protocol and gave 
their support, as evidenced by the comments at the end of the AGREE II table. All of the 
studies compared the medication against a placebo or a drug in another class. No reviews 
compared medicines within the same type. This methodology did not allow direct 
comparison of drugs within a category. This lack of having  a direct comparison between 
medications in a class, prevents knowing which medication in the class is expected to 
provide the most A1c reduction, weight reduction, and possibly the most CV risk 
reduction.. Without this information, it is a challenge to determine which medication is 
the most appropriate one to use.  Moreover, lack of specific information means that 
practitioners do not have the educational support they need to use the most effective 
medication. This same lack of direct comparison also posed a challenge to the effort to 
compare drugs for use in this review for the guideline.  
An additional limitation is that newer diabetes medications continue to be in the 
development stage and in clinical trials. Additionally, studies are currently in process to 
show CVD risk reduction as well as other benefits such as fatty liver reduction, slowing 
of renal function decline, and lower risk of other diseases and conditions. 
Perhaps the most challenging limitation is that new research is frequently released 
that provides new insights into the benefits of diabetes medications. This dynamic 
activity further complicates diabetes management.  
33 
 
Summary 
 The determination to choose the most appropriate medication to manage and treat 
T2DM remains a challenge for providers. First, newer medications and newer study 
outcomes are both in a dynamic state, and second, limited data allow direct comparison 
of the medications within a class. This paper, now finished, is nearly outdated. This 
situation makes diabetes management even more challenging than in the past. However, 
even with these limitations, this protocol allows a single resource to assist practitioners in 
making more appropriate choices for medication use and titration. 
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Section 5: Dissemination Plan 
 In this paper, I have reviewed a current algorithm/protocol to assist practitioners 
in treating T2DM patients. I conducted literature searches to review the medications in 
the current protocol to determine current information regarding their use, safety, side 
effects, and cost. I assembled an expert panel of providers, provided them with the 
current draft of this paper, and used the AGREE II tool to systematically review the 
literature as presented herein and to determine whether the current protocol tool should 
be modified and, if so, how. These results led to the determination that the current tool 
remains appropriate and current.  
 Using this information, I will present the results to the members of the DCTC 
group at their February 2020 monthly meeting. As a member of this committee, I also 
personally tasked myself with staying current with diabetes management and will present 
new information at future meetings. With this new information, the committee has the 
authority to revise the protocol. The DCTC group is also challenged with the 
dissemination of diabetes management to the entire healthcare system.   
Analysis of Self 
 This project assisted my professional growth and my personal growth in many 
ways. Professionally, I worked with the medical director of the health care system. This 
led to an increase in our respect for each other. This interaction also supported me in 
proving my value as a member of the DCTC. In our most recent email exchange, the 
medical director signed with his first name. He also said that he is “appreciative of all I 
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do” in providing diabetes education. This paper’s completion was also a goal for my 
professional growth toward my personal goals as an employee of this healthcare system.  
 I came to realize that when I look at a project, I tend to look at the entire project 
and see a mass of smaller sections. As a result of this paper, I recognize the need to take a 
whole project and break it down into smaller, more manageable tasks. Then, when a  task 
is completed, I can feel a sense of accomplishment and can feel energized to take on the 
next smaller task. This revelation has already moved over into my professional life. I see 
more positive responses from my coworkers and family than I have ever received in the 
past. 
Summary 
Diabetes management has become a complicated process with the advent of new 
classes and new medications within classes. The protocol described in this document is 
helpful in assisting providers with a one-page resource to support them in diabetes 
management. This review determined that the current protocol remains current and 
appropriate for use. The health care system has a process in place for dissemination. As a 
member of the committee that is charged with diabetes oversight for the system, I will be 
able to influence and drive changes if and when these changes are published in evidence-
based professional journals and other information sources.  
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